Replies to post #483782 on Anavex Life Sciences Corp (AVXL)

[BIOChecker4]

None of this is new. These topics have been discussed here for years. I don’t think any of these criticisms or suggestions would be new to Missling. Missling does not have any interest in anybody’s advice. He does what he wants and that’s it. He can’t even bother to work with a communications professional to improve his presentation skills. He’s making millions and is unaccountable to his board or to shareholders. He has a job for life. What, then, would be his motivation?

Most of the institutions that hold AVXL are index funds, not actively managed biotech funds. The heavy hitters in biotech are on the sidelines. Whether they don’t believe in the technology or don’t believe in Missling or both is a huge unanswered question. However, Missling has done little to give serious biotech investors comfort.

Nobody should expect Missling to do anything other than what he has been doing all along. After all, it’s worked for him. At this point, Blarcamesine will either be approved or not. That’s it.

If some people are smart enough to make money trading AVXL, good for them.

[kund]

I thought Jiong Ma was the president of the company. There was a vote back in 2022/23 to separate responsibilities from TGD, but it looks like he is still the president. The Anavex website and 10-K filings still list him as president.

This company has become his personal playground. He operates with an iron fist, which is why Wall Street has no respect for him.

[Hoskuld]

None of that makes any sense, BAR123. CM converts all his options to shares except those shares he needs to liquidate to cover transaction costs. Insider buys are NBD. And CM isn't going anywhere: 11 years of planning play out this year.

Short covering will happen when it happens. Generally that happens when material events make shorting unattractive. That is what we are all waiting for. Last year we sat around $4-$5 per share this year we sit at $8-$9 per share because MAA was filed and peer review was published and OLE results are good.

Buyback is not going to happen. The company sells shares regularly to keep capital on hand high enough to give them flexibility. They are not going to rebuy what they are selling

This is pre-revenue biotech: share are massively f***ed with until the game suddenly ends. That will happen soon.

[meds4life]

At an annual investor meeting I asked staff ( including IR guy if I remember right ) to show confidence in our drug results by purchasing some significant amount of AVXL shares to show they're putting some skin in the game. Most unenthusiastic responses followed.

[D-Mike]

That’s the best “rant” I’ve read in quite some time. Keep them coming. I’ve had many of the same thoughts recently. I to have talked to IR. My experience is that there is no “team” just Clint and he’s unimpressive.